A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

NCT06643585 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

180

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab-Deruxtecan
OTHER: Physicians Choice (PhC).

Sponsor

Prof. Wolfgang Janni